论文部分内容阅读
进攻性联合化疗后继发恶性肿瘤的危险最大,但单一化疗后也可发生。本文报道1例胰岛细胞癌长期使用链脲霉素治疗后发生急性粒细胞白血病。患者男性,69岁。腹痛2年,盆腔 X 线检查有成骨细胞的损害。1974年6月剖腹探查证实为胰岛细胞癌伴网膜和肝转移。同年11月开始至1976年6月,每2～4个月用链脲霉素5周,剂量为1.0g/m~2周。以后改为500mg/m~2/周,直到1977年3月。此时血白细胞3,400,分类正常,血球压积37.5%,血小板128,000。患者在28个月内共用链脲霉素67g。1977年7月为患者体检无肿瘤迹象,肝扫描、骨检查、血清促胃液素及肝功能也均正常。白细胞2,300,中性分叶48%、淋巴43%,血球压积42.3%,
The risk of secondary malignancies is greatest after aggressive combination chemotherapy, but may occur even after single chemotherapy. This article reports a case of pancreatic islet cell carcinoma of the long-term use of streptozotocin after treatment of acute myeloid leukemia. Male patient, 69 years old. 2 years of abdominal pain, pelvic X-ray examination of osteoblasts damage. June 1974 laparotomy confirmed pancreatic islet cell carcinoma with retinal and liver metastases. The same year from November to June 1976, every 2 to 4 months with streptozotocin 5 weeks, a dose of 1.0g / m ~ 2 weeks. Later changed to 500mg / m ~ 2 / week until March 1977. At this time 3,400 blood white blood cells, normal classification, hematocrit 37.5%, 128,000 platelets. Patients share streptozotocin 67g within 28 months. July 1977 for medical examination of patients with no signs of tumor, liver scan, bone examination, serum gastrin and liver function are also normal. Leukocyte 2,300, neutral lobe 48%, lymph 43%, hematocrit 42.3%